In warranty program, Pfizer will refund up to $50K for patients who discontinue use of rare disease drug

Over the last several years however, some drugmakers have begun to experiment with money-back guarantees for their products.

Count Pfizer among them. Last year the pharma giant introduced its first warranty program, using it to promote lung cancer drug Xalkori. Now Pfizer has opened a similar program for newly approved Panzyga, which treats the rare disorder chronic inflammatory demyelinating polyneuropathy (CIPD).